Differential pricing of new pharmaceuticals in lower income European countries

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 6, 2013, Pages 735-741

  Kaló, Zoltán ^a,b   Annemans, Lieven ^c,d   Garrison, Louis P ^e  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b Syreon Research Institute   (Hungary)

^c GHENT UNIVERSITY   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Central Eastern Europe; confidential pricing agreements; international price referencing; patient access; pharmaceutical pricing policy; Ramsey optimal pricing; risk sharing

Indexed keywords

NEW DRUG;

DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; EUROPE; EUROPEAN UNION; FEASIBILITY STUDY; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; LOWEST INCOME GROUP; POPULATION SIZE; REVIEW;

COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EUROPE; HUMANS; INCOME; PHARMACEUTICAL PREPARATIONS; POLICY MAKING;

EID: 84887913110     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2013.847367     Document Type: Review

References (24)

1. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada. JAMA 302(13), 1437-1443 (2009).
2. Drummond M, Jonsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 12, 263-271 (2011).
3. Godman B, Gustafsson LL. A new reimbursement systems for innovative pharmaceuticals combining value-based and free market pricing. Appl. Health Econ. Health Policy 11, 79-82 (2013).
4. Annemans L, Cleemput I, Hulstaert F, Simoens S. Valorising and creating access to innovative medicines in the European Union. Front. Pharmacol. 2(57), 1-6 (2011).
5. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. Directorate general for internal policies, policy department A: Economic and scientific policy. European Parliament, Brussels, Belgium (2011).
6. Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good research practices in cost-effectiveness analyses: A societal perspective: The ISPOR drug cost task force report - part II. Value Health 13(1), 8-13 (2010).
7. Ramsey FP. A contribution to the theory of taxation. Econ. J. 37, 47-61 (1927).
8. Hay JW, Smeeding J, Carroll NV et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: The ISPOR drug cost task force report - part I. Value Health 13(1), 3-7 (2010).
9. Danzon PM. Making sense of drug prices. Regulation 23(1), 56-63 (2000).
10. OECD Health Policy Studies. Pharmaceutical Pricing Policies in a Global Market. OECD Publishing, Paris, France (2008).
11. Vogler S, Habl C, Leopold C et al. Vienna, PPRI Report. Gesundheit osterreich GmbH/Geschaftsbereich oBIG, Vienna (2008).
12. Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 23(7), 651-658 (2005).
13. Kaló Z, Docteur E, Mose P. Pharmaceutical Pricing and Reimbursement Policies in Slovakia, OECD Health Working Paper, No. 31, p.14. OECD, Paris (2008).
14. Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs 25(2), 313-324 (2006).
15. Danzon PM. Price discrimination for pharmaceuticals: welfare effects in the US and the EU. Int. J. Econ. Bus. 4(3), 301-321 (1997).
16. Carlson JJ, Garrison LP, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J. Manag. Care Pharm. 15(8), 683-687 (2009).
17. Towse A, Garrison LP. Can't get no satisfaction will pay for performance help toward an economic framework for understanding performance-based risksharing agreements for innovative medical products. Pharmacoeconomics 28(2), 93-102 (2010).
18. Coulton L, Annemans L, Carter R et al. Outcomes-based risk-sharing schemes-is there a potential role in the Asia-Pacific markets Health Outcomes Res. Med. (3)4, e205-e219 (2012).
19. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3), 179-190 (2010).
20. Kaló Z, Vokó Z. The role of risk sharing in drug funding (in Hungarian). LAM 20(3-4), 237-241 (2010).
21. Orlewska E. Challenges and changes in the polish healthcare system. Soc. Econ. 33(3) 575-594 (2011).
22. Garau M, Towse A, Danzon P. Pharmaceutical pricing in Europe: is differential pricing a win-win solution occasional paper 11/01, office of health economics, London (2011).
23. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3(3), 183-205 (2003).
24. Danzon PM, Towse A, Mulcahy AW: Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff. 30(3), 1529-1538 (2011).